Skip to content
DataLookout
Menu

NCT07756580

A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar Lines

StatusActive, Not Recruiting
PhasePhase 1
SponsorAbbVie
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 6 words Show 4 more changesShow less
    • Enrollment closed, study ongoing
    • Final enrollment: 143 participants (planned 120)
    • Primary completion date: Mar 2027 to Feb 2027
    • Site details revised at 8 of 8 sites
  2. Notable Recruitment opened
    • Trial sites expanded: 0 → 8 locations
    v3
  3. Minor Study sites: 1 to 0v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Participants with Adverse Events (AEs)
Timeframe: Up to Approximately Day 141

Arms and interventions

Cohort 1 - AGN-151586 and BOTOXExperimental

Participants will receive AGN-151586 on Day 1, followed by BOTOX on Day 14.

Cohort 2 - AGN-151586 and BOTOXExperimental

Participants will receive AGN-151586 on Day 1, followed by BOTOX on Day 21.

Drugs: AGN-151586, BOTOX

Sites

8 sites in 1 country